Accession Number:

ADA553566

Title:

Rosiglitazone and Fenofibrate Additive Effects on Lipids

Descriptive Note:

Journal article

Corporate Author:

BROOKE ARMY MEDICAL CENTER FORT SAM HOUSTON TX

Report Date:

2011-10-01

Pagination or Media Count:

5.0

Abstract:

To evaluate the effect of rosiglitazone, fenofibrate, or their combined use on plasma lipids in normoglycemic healthy adults.Methods and Results. Subjects were randomized in a double-blind fashion to rosiglitazone placebo, fenofibrate placebo, rosiglitazone fenofibrate, or matching double placebo. The between-group difference in the change in fasting TG, high-density lipoprotein cholesterol HDL-C, LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of treatment. A total of 548 subjects were screened and 41 met the inclusion criteria. After 12 weeks of therapy, the median change in the triglyceride levels showed a significant reduction ranging from 47 to 55 mg per deciliter in the fenofibrate only and rosiglitazone fenofibrate groups compared with placebo P 0.0496. However, the rosiglitazone only group did not show significant change in triglyceride level. The change in the Apo AII showed increase in all the treatment groups compared with placebo P 0.009. There was also significant change in the Apo CIII that showed reduction of its level in the fenofibrate only and rosiglitazone fenofibrate groups P 0.0003. Conclusion. Rosiglitazone does not appear to modulate hypertriglyceridemia in patients with elevated triglycerides independent of glucose metabolism.

Subject Categories:

  • Medicine and Medical Research
  • Microbiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE